Literature DB >> 15000155

Treatment of colorectal cancer metastasis: the role of chemotherapy.

Henry Q Xiong1, Jaffer A Ajani.   

Abstract

5-Fluorouracil (5-FU) has been the main chemotherapeutic agent for the treatment of colorectal cancer for four decades with modest efficacy. Modulation of 5-FU by leucovorin or continuous infusion improves the response rate, but overall survival duration remains approximately 12 months. Many oral fluoropyrimidines have been studied, including capecitabine, UFT, S-1, and Eniluracil. Capecitabine has demonstrated equivalent efficacy with 5-FU and has been approved as first line treatment. The combinations of capecitabine with CPT-11 or oxaliplatin are being developed. CPT-11 demonstrated non-crossover resistance with 5-FU and was proven to be effective treatment for patients who received prior 5-FU. CPT-11 in combination with 5-FU has demonstrated improved response rate and overall survival duration over 5-FU or CPT-11. Oxaliplatin plus 5-FU has offered another effective treatment option for colorectal cancer. Both 5-FU plus leucovorin in combination with CPT-11 or oxaliplatin are widely used first-line chemotherapies for advanced colorectal cancer. Optimal combinations and sequences of treatment are being studied, since several effective regimens have become available.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15000155     DOI: 10.1023/a:1025823315416

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  2 in total

Review 1.  Tumor metastasis: Mechanistic insights and therapeutic interventions.

Authors:  Mengmeng Liu; Jing Yang; Bushu Xu; Xing Zhang
Journal:  MedComm (2020)       Date:  2021-12-02

2.  Irinotecan Plus S-1 Followed by Hepatectomy for a Patient with Initially Unresectable Colorectal Liver Metastases, Who Showed Severe Drug Rash with Oxaliplatin Plus 5-FU and Leucovorin (FOLFOX).

Authors:  Hiroyuki Komori; Toru Beppu; Yasuo Sakamoto; Yuji Miyamoto; Hiromitsu Hayashi; Katsunori Imai; Hidetoshi Nitta; Masayuki Watanabe; Hideo Baba
Journal:  Case Rep Gastrointest Med       Date:  2014-06-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.